当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation.

HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation.

Abstract：

:HLA-C matching is an important determinant of outcome after myeloablative unrelated donor (URD) hematopoietic stem cell transplantation. However, its importance in non-myeloablative stem cell transplantation (NST) is not known. We report a retrospective analysis of 111 patients who underwent URD NST, of whom 78 were 10/10 matched at HLA-A, B, C, DRB1, DQB1 and 33 were mismatched at one or more HLA-C antigen/allele (24 HLA-C only; nine HLA-C+other locus mismatch). Patients were conditioned with busulfan (0.8 mg/kg/day i.v. x 4 days) and fludarabine (30 mg/m(2)/day i.v. x 4 days). Graft-versus-host disease prophylaxis included cyclosporine/prednisone- or tacrolimus/mini-methotrexate-based regimens. HLA-C disparity did not impair engraftment. Median marrow donor chimerisms were >or=90% donor at day+30 and +100 in both groups. Overall survival at 2 years was 30% in HLA-C-mismatched and 51% in 10/10-matched patients (P=0.008). In Cox regression, HLA-C mismatch was an independent predictor of death (hazard ratio 1.85, P=0.04). Treatment-related mortality was higher in the HLA-C-mismatched group: 48 versus 16% (P=0.0001). Cumulative relapse incidence was 35% in the HLA-C-mismatched and 55% in the 10/10-matched cohort, P=0.09. HLA-C mismatch is associated with inferior survival after URD NST.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Ho VT,Kim HT,Liney D,Milford E,Gribben J,Cutler C,Lee SJ,Antin JH,Soiffer RJ,Alyea EP

doi

10.1038/sj.bmt.1705315

subject

Has Abstract

pub_date

2006-05-01 00:00:00

pages

845-50

issue

9

eissn

0268-3369

issn

1476-5365

pii

1705315

journal_volume

37

pub_type

杂志文章,多中心研究

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and ce

    abstract：:We evaluated the 100-day mortality rates associated with busulfan-based myeloablative conditioning regimens based on data from 1812 chronic myelogenous leukemia patients who underwent allogeneic blood or marrow transplantation (allotx). In all, 47 patients received intravenous (i.v.) busulfan and cyclophosphamide (i.v...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1704461

    authors： Thall PF,Champlin RE,Andersson BS

    更新日期：2004-06-01 00:00:00

  • Allogeneic marrow transplantation using T cell depletion for patients with juvenile chronic myelogenous leukemia without HLA-identical siblings.

    abstract：:Six children with clinical and hematologic features of juvenile chronic myelogenous leukemia (JCML) underwent bone marrow transplantation (BMT) using T cell-depleted marrow from non-HLA-matched related or closely HLA-matched unrelated donors. Patient ages ranged from 1.2 to 5 years. Four patients received cytoreductiv...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Bunin NJ,Casper JT,Lawton C,Murray K,Camitta BM,Greenwood M,Geil J,Ash RC

    更新日期：1992-02-01 00:00:00

  • Gene therapy of chronic granulomatous disease.

    abstract：:Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder which results from absence or malfunction of the respiratory burst oxidase normally expressed in neutrophils and other phagocytic leukocytes. Two-thirds of the patients are males hemizygous for mutations in the X-linked gene coding for gp91-pho...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702365

    authors： Grez M,Becker S,Saulnier S,Knöss H,Ott MG,Maurer A,Dinauer MC,Hoelzer D,Seger R,Hossle JP

    更新日期：2000-05-01 00:00:00

  • Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients.

    abstract：:Cord blood (CB) transplantation is an alternate source of human hematopoietic progenitor cells for allogeneic stem cell transplantation in children and adolescents with both malignant and nonmalignant diseases. Current limitations included delay in hematopoietic reconstitution, increased incidence of primary graft fai...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2015.196

    authors： Cairo MS,Tarek N,Lee DA,Delaney C

    更新日期：2016-01-01 00:00:00

  • Towards a global system of vigilance and surveillance in unrelated donors of haematopoietic progenitor cells for transplantation.

    abstract：:Safety of living donors is critical to the success of blood, tissue and organ transplantation. Structured and robust vigilance and surveillance systems exist as part of some national entities, but historically no global systems are in place to ensure conformity, harmonisation and the recognition of rare adverse events...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2013.104

    authors： Shaw BE,Chapman J,Fechter M,Foeken L,Greinix H,Hwang W,Phillips-Johnson L,Korhonen M,Lindberg B,Navarro WH,Szer J

    更新日期：2013-11-01 00:00:00

  • Impact of pretransplant donor-specific anti-HLA antibodies on cord blood transplantation on behalf of the Transplant Complications Working Group of Japan Society for Hematopoietic Cell Transplantation.

    abstract：:Graft failure (GF) remains a major complication of cord blood transplantation (CBT). Although the presence of pretransplant, donor-specific anti-HLA antibodies (DSA) was reported to be associated with an increased risk of GF after CBT, data are still limited. Thus, we conducted a retrospective analysis of recipients o...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-019-0712-0

    authors： Fuji S,Oshima K,Ohashi K,Sawa M,Saito T,Eto T,Tanaka M,Onizuka M,Nakamae H,Shiratori S,Ozawa Y,Hidaka M,Nagamura-Inoue T,Tanaka H,Fukuda T,Ichinohe T,Atsuta Y,Ogata M

    更新日期：2020-04-01 00:00:00

  • Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia.

    abstract：:Through two consecutive trials, a policy that considered allogeneic stem cell transplantation (SCT) from a sibling donor in second rather than first complete remission (CR) in selected younger patients with acute myeloid leukemia (AML) with t(8;21)/inv(16) (core binding factor (CBF) group) or a normal karyotype (NN gr...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1704884

    authors： de Labarthe A,Pautas C,Thomas X,de Botton S,Bordessoule D,Tilly H,de Revel T,Bastard C,Preudhomme C,Michallet M,Fenaux P,Bastie JN,Socié G,Cordonnier C,Dombret H,Acute Leukemia French Association.

    更新日期：2005-04-01 00:00:00

  • Psychosocial adaptation of patients and families following bone marrow transplantation: a prospective, longitudinal study.

    abstract：:Using a prospective, repeated measures design, this study investigated the psychosocial functioning of patients and a close relative pre- and post-allogeneic and autologous bone marrow transplantation (BMT). All patients (n = 28) undergoing BMT in a 1 year period, and their relatives, were interviewed 1 week pre-trans...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701443

    authors： Keogh F,O'Riordan J,McNamara C,Duggan C,McCann SR

    更新日期：1998-11-01 00:00:00

  • Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study.

    abstract：:Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n=38), donor pretransplant vaccination (n=44) or ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/bmt.2015.47

    authors： Ambati A,Boas LS,Ljungman P,Testa L,de Oliveira JF,Aoun M,Colturato V,Maeurer M,Machado CM

    更新日期：2015-06-01 00:00:00

  • Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease.

    abstract：:Glucocorticoids for primary therapy of acute GVHD have limited responses. A phase I/II trial tested 4 weeks of deacetylase inhibitor panobinostat started within 48 h of glucocorticoids (1 mg/kg/day prednisone or equivalent) as primary treatment for patients with either classic acute GVHD (n = 16) or acute GVHD overlap...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-018-0163-z

    authors： Perez L,Fernandez H,Horna P,Riches M,Locke F,Field T,Powers J,Sahakian E,Villagra A,Mishra A,Betts B,Kharfan-Dabaja M,Beato F,Ochoa-Bayona L,Pidala J,Anasetti C

    更新日期：2018-11-01 00:00:00

  • Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.

    abstract：:Fifty patients with either lymphoid or selected solid tumor malignancies were apheresed an identical number of times for PBSC collection after being randomized to receive either G-CSF 10 microg/kg/day alone (arm I), or G-CSF at the same dose with GM-CSF 5 microg/kg/day (arm II). Growth factor(s) was/were given as the ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1038/sj.bmt.1700999

    authors： Spitzer G,Adkins D,Mathews M,Velasquez W,Bowers C,Dunphy F,Kronmueller N,Niemeyer R,McIntyre W,Petruska P

    更新日期：1997-12-01 00:00:00

  • The Japan Marrow Donor Program, 25 years of experience in achieving 20,000 bone marrow transplantations: organization structure, activity, and financial basis.

    abstract：:The Japan Marrow Donor Program (JMDP), established in 1991, has continued to grow in its capacity to facilitate unrelated bone marrow (BMT) and peripheral blood stem cell transplantation (PBSCT) for the past 25 years in Japan. The current donor pool is 463,465 (as of 31 December 2016) and 20,237 transplants were perfo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-017-0084-2

    authors： Saito H,Ito M,Kato S,Kodera Y,Okamoto S,Taniguchi S,Takanashi M,Kanamori H,Masaoka T,Takaku F,JMDP.

    更新日期：2018-05-01 00:00:00

  • A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation.

    abstract：:Allogeneic hematopoietic stem cell transplantation (ASCT) and its conditioning with chemoradiotherapy often results in liver toxicity, the most severe form being veno-occlusive liver disease (VOD). N-acetyl-L-cysteine (NAC), an antioxidant glutathione precursor, may provide protection from liver toxicity. Patients wit...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/sj.bmt.1705969

    authors： Barkholt L,Remberger M,Hassan Z,Fransson K,Omazic B,Svahn BM,Karlsson H,Brune M,Hassan M,Mattsson J,Ringdén O

    更新日期：2008-05-01 00:00:00

  • Combined foscarnet -ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct).

    abstract：:Thirty two allogeneic bone marrow transplant (BMT) recipients, aged 16-55 (median 35), with CMV antigenemia (= > 5 positive cells) developing at a median interval from BMT of 49 days, were given combined treatment with foscarnet and ganciclovir for 15 days. Maintenance was given with foscarnet and ganciclovir on alter...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Bacigalupo A,Bregante S,Tedone E,Isaza A,Van Lint MT,Moro F,Trespi G,Occhini D,Gualandi F,Lamparelli T,Marmont AM

    更新日期：1996-11-01 00:00:00

  • Hemopoietic stem cell processing: comparison of progenitor cell recovery using the Cobe 2991 cell washer and the Haemonetics V50 apheresis system.

    abstract：:Using 24 bone marrow (BM) harvests intended for cryopreservation and transplantation, we compared the use of the Cobe 2991 cell washer (2991) and the Haemonetics V50 apheresis system (HV50) for automated BM processing. Our in vitro data indicate that while the mononuclear cell (MNC) concentration of the HV50 product w...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Preti RA,Ahmed T,Ayello J,Helson L,Argani I,Wuest D,Ciavarella D

    更新日期：1992-05-01 00:00:00

  • Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.

    abstract：:Relapse is a serious complication following high-dose therapy and autologous bone marrow transplantation (ABMT) for malignant lymphoma (ML). Allogeneic transplantation (alloSCT) is a therapeutic option. However, it is associated with a high incidence of transplant-related organ toxicity and mortality. We recently repo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702392

    authors： Nagler A,Slavin S,Varadi G,Naparstek E,Samuel S,Or R

    更新日期：2000-05-01 00:00:00

  • Early herpes zoster infection in adult patients with Hodgkin's disease undergoing autologous bone marrow transplant.

    abstract：:The incidence of varicella-zoster-virus infection/reactivation in adult patients with Hodgkin's disease undergoing autologous bone marrow transplantation (BMT) at the University of Minnesota Hospital and Clinic was determined. Seven of 28 evaluable patients (25%) developed varicella-zoster infections in the first 150 ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Christiansen NP,Haake RJ,Hurd DD

    更新日期：1991-06-01 00:00:00

  • Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies.

    abstract：:We report results of a thiotepa-based conditioning in haploidentical stem cell transplantation (haplo-SCT) with posttransplant cyclophosphamide (PT-CY) and antithymocyte globulin (ATG), for unmanipulated peripheral blood stem cell (PBSC) transplants, in 80 patients with hematological malignancies. Patients in complete...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-019-0726-7

    authors： Peric Z,Mohty R,Bastos J,Brissot E,Battipaglia G,Belhocine R,Sestili S,Giannotti F,Vekhoff A,Ledraa T,Legrand O,Lapusan S,Isnard F,Labopin M,Bonnin A,Mediavilla C,Rubio MT,Ruggeri A,Duléry R,Malard F,Mohty M

    更新日期：2020-04-01 00:00:00

  • Major salivary gland dysfunction in human acute and chronic graft-versus-host disease (GVHD).

    abstract：:Salivary gland dysfunction is frequently observed in patients suffering from acute (a) and chronic (c) GVHD. We studied the influence of GVHD on the function of major salivary glands in 20 patients with GVHD (cGVHD, 15; aGVHD, 5). A subjective evaluation of salivary function was performed, in which the score ranged fr...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Nagler R,Marmary Y,Krausz Y,Chisin R,Markitziu A,Nagler A

    更新日期：1996-02-01 00:00:00

  • Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation.

    abstract：:We investigated the nature of hemostatic alterations occurring after bone marrow transplantation. In 45 patients, we evaluated the coagulation parameters, naturally occurring anticoagulants and thrombomodulin at days +15 and +22 after conditioning therapy. It was observed that endothelial cell damage is a central path...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Testa S,Manna A,Porcellini A,Maffi F,Morstabilini G,Denti N,Macchi S,Rosti G,Porcellini G,Cassi D,Ferrari L

    更新日期：1996-08-01 00:00:00

  • Treatment of leukemic relapse following unrelated umbilical cord blood transplantation with interleukin-2: potential for augmenting graft-versus-leukemia and graft-versus-host effects with cytokines.

    abstract：:In comparison to bone marrow, umbilical cord blood has decreased intrinsic immune responsiveness allowing transplantation across HLA barriers with lower rates of graft-versus-host disease. However, laboratory models have also suggested that cord blood may be extremely sensitive to stimulation by cytokines. We report a...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702520

    authors： Goldberg SL,Pecora AL,Rosenbluth RJ,Jennis AA,Preti RA

    更新日期：2000-08-01 00:00:00

  • A novel minor histocompatibility antigen recognized by HLA-A31 restricted cytotoxic T lymphocytes generated from HLA-identical bone marrow donor lymphocytes.

    abstract：:Bulk cytotoxic T lymphocytes (CTL) were generated by in vitro stimulation of BMT donor lymphocytes with Philadelphia chromosome (Ph)-positive leukemic cells from an HLA-identical sibling patient. CTL were cytotoxic against the patient's leukemic cells as well as the EBV-lymphoblastoid cell line (EBV-LCL) generated fro...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701856

    authors： Yazaki M,Takahashi T,Andho M,Akatsuka Y,Ito T,Miyake Y,Ito Y,Nakamura S,Wada Y

    更新日期：1999-07-01 00:00:00

  • Hepatic veno-occlusive disease with severe capillary leakage after peripheral stem cell transplantation: treatment with recombinant plasminogen activator and C1-esterase inhibitor concentrate.

    abstract：:Severe veno-occlusive disease (VOD), characterised by elevated serum bilirubin levels, is a known complication in the first 3 weeks after peripheral blood stem cell transplantation (PBSCT). Severe VOD is associated with capillary leakage and multiple organ dysfunction and leads to high mortality. We report a 17-year-o...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701211

    authors： Heying R,Nürnberger W,Spiekerkötter U,Göbel U

    更新日期：1998-05-01 00:00:00

  • Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation.

    abstract：:Posttransplant cyclophosphamide (PTCy:100 mg/kg) has been increasingly used in allogeneic hematopoietic stem cell transplantation, however, few studies compared different doses of PTCy. We conducted two consecutive prospective multicenter phase II studies to evaluate the safety and efficacy of 80 mg/kg of PTCy in 137 ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-01065-0

    authors： Sugita J,Kamimura T,Ishikawa T,Ota S,Eto T,Kuroha T,Miyazaki Y,Kumagai H,Matsuo K,Akashi K,Taniguchi S,Harada M,Teshima T

    更新日期：2020-09-24 00:00:00

  • Effects of radiation and 4-hydroperoxycyclophosphamide on production of G- and GM-CSF by stromal cells.

    abstract：:The effects of in vitro radiation and exposure to 4-hydroperoxycyclophosphamide (4-HC) on the production of G- and GM-CSF by different components of the human hematopoietic microenvironment are described. The marrow microenvironment is composed of fibroblasts, endothelial cells, macrophages, and adipocytes. To study t...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Laver JH,Xu F,Barredo JC,Abboud MR

    更新日期：1992-12-01 00:00:00

  • Low T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC.

    abstract：:We investigate the feasibility of CD34-selected peripheral blood stem cell (PBSC) transplantation followed by pre-emptive CD8-depleted donor lymphocyte infusions (DLI) after a minimal conditioning regimen. Six patients with advanced hematological malignancies ineligible for a conventional myeloablative transplant (n=5...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1704220

    authors： Baron F,Baudoux E,Frère P,Tourqui S,Schaaf-Lafontaine N,Herens C,DePrijck B,Fillet G,Beguin Y

    更新日期：2003-10-01 00:00:00

  • Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients.

    abstract：:In 2005, the National Institutes of Health (NIH) chronic graft-versus-host disease (cGVHD) consensus project provided diagnosis and staging criteria, based mostly on clinical experience and expert opinion. These criteria were revised in 2014, aiming to provide enhanced specificity and clarity. However, the impact of 2...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/s41409-018-0224-3

    authors： Kerep AZ,Broome J,Pirsl F,Curtis LM,Steinberg SM,Mitchell SA,Cowen EW,Pichard DC,Joe GO,Comis LE,Mays JW,Datiles MB 3rd,Stratton P,Zolton J,Berger A,Hendricks J,Kenyon M,Baruffaldi J,Titarenko I,Pulanic D,Baird K

    更新日期：2019-01-01 00:00:00

  • Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma.

    abstract：:Fifty-five patients with advanced multiple myeloma received purified CD34-selected peripheral blood progenitor cell transplants following myeloablative chemotherapy. A median of 4.1 x 10(6) CD34 cells/kg (range 1.2-30.7) were infused after busulfan (14 mg/kg) and cyclophosphamide (120 mg/kg); granulocyte-macrophage co...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1701055

    authors： Schiller G,Vescio R,Freytes C,Spitzer G,Lee M,Wu CH,Cao J,Lee JC,Lichtenstein A,Lill M,Berenson R,Berenson J

    更新日期：1998-01-01 00:00:00

  • Haplotype mismatched transplantation using high doses of peripheral blood CD34+ cells together with stratified conditioning regimens for high-risk adult acute myeloid leukemia patients: a pilot study in a single Korean institution.

    abstract：:A total of 11 high-risk Korean acute myeloid leukemia (AML) patients received stem cell transplantation from human leukocyte antigen (HLA) haploidentical donors. Specifically, for eight patients with 2-3 mismatched antigens and bidirectional vectors, we used a newly designed conditioning regimen that consists of total...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704900

    authors： Kim HJ,Min WS,Kim YJ,Kim DW,Lee JW,Kim CC

    更新日期：2005-05-01 00:00:00

  • Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma.

    abstract：:We present three patients with aggressive non-Hodgkin's B-cell lymphoma (NHL) who received anti-CD19 chimeric antigen receptor T (CAR T) cells therapy after failure of several lines of chemotherapy that developed pseudo-progression. One-week clinical and radiological findings were consistent with tumor progression. Po...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-01156-y

    authors： Danylesko I,Shouval R,Shem-Tov N,Yerushalmi R,Jacoby E,Besser MJ,Shimoni A,Davidson T,Beider K,Mevorach D,Fried S,Nagler A,Avigdor A

    更新日期：2020-12-03 00:00:00